ClinicalTrials.gg

Program

ruzinurad

Also written as “SHR4640”, “SHR4640 tablet” and “SHR4640 dose1”.

Its studies are mostly in Hyperuricemia · Gout, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Aug 6, 201920 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine201 open or runningphase 3since Aug 6, 2019Apr 27, 2016Jul 2027phase 2 · NCT07362355

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Apr 27, 2016.

  1. Jun 27, 2017Phase 1 study in GoutNCT03211403 · 24 enrolled · Australia
  2. Aug 6, 2019Phase 3 study in GoutNCT04052932 · 594 enrolled · China
  3. Nov 4, 2019Phase 1 study in HyperuricemiaNCT04157959 · 28 enrolled · China
  4. Nov 26, 2019Phase 2 study in HyperuricemiaNCT04180982 · 84 enrolled
  5. Jan 20, 2020Phase 1 study in Healthy Adult Male VolunteersNCT04260373 · 6 enrolled · China
  6. Mar 10, 2020Phase 1 study in Hepatic ImpairmentNCT04305392 · 24 enrolled · China
  7. Sep 27, 2020Phase 1 study in HyperuricemiaNCT04586803 · 24 enrolled
  8. Nov 3, 2020Phase 1 study in Healthy SubjectsNCT04620408 · 14 enrolled
  9. Apr 19, 2021Phase 1 study in Healthy Male SubjectsNCT04850638 · 18 enrolled · China
  10. Jul 7, 2021Phase 3 study in GoutNCT04956432 · 779 enrolled · China
  11. Aug 22, 2022Phase 2 study in HyperuricemiaNCT05513976 · 129 enrolled
  12. Jul 13, 2023Phase 1 study in HyperuricemiaNCT05954169 · 16 enrolled · China
  13. Dec 5, 20232 phase 1 studiesNCT06168929, NCT06196580
  14. Jan 15, 2026Phase 2 study in HyperuricemiaNCT07362355 · 340 planned · China

Ahead

  1. Jul 2027Primary completion: phase 2 study in HyperuricemiaNCT07362355

TargetBeta

SLC22A12 →read by rule
“Solute carrier family 22 member 12 inhibitor”ChEMBL 37, by rule

Other programs on SLC22A12

ProgramCompanyFurthest phaseStudies
dotinuradrulefuji-yakuhin-co-ltdphase 322

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07362355Hyperuricemia · China2RecruitingJul 2027340
NCT06196580Gout · China1CompletedFeb 16, 202424
NCT06168929Hyperuricemia · China1CompletedJan 13, 202434
NCT05954169Hyperuricemia · China1CompletedJul 1, 202416
NCT05513976Hyperuricemia2UNKNOWNMay 30, 2023129
NCT04956432Gout · China3CompletedDec 13, 2023779
NCT04850638Healthy Male Subjects · China1CompletedSep 5, 202118
NCT04620408Healthy Subjects1UNKNOWNJan 202114
NCT04586803Hyperuricemia1UNKNOWNNov 202024
NCT04305392Hepatic Impairment · China1UNKNOWNDec 202224
NCT04260373Healthy Adult Male Volunteers · China1CompletedApr 3, 20206
NCT04180982Hyperuricemia2UNKNOWNJul 30, 202084
NCT04157959Hyperuricemia · China1UNKNOWNJun 1, 202028
NCT04052932Gout · China3CompletedJul 14, 2021594
NCT03211403Gout · Australia1CompletedFeb 15, 201824
NCT03185793Hyperuricemia · China2CompletedJul 20, 2018198
NCT03131583Gout · China1CompletedJan 29, 201815
NCT03015948Gout · Australia1CompletedNov 23, 201640
NCT02890966Gout · China1CompletedFeb 201748
NCT02815839Gout · China1CompletedFeb 201750

How it is read

Names in the registry

  • “SHR4640”, 15 entries
  • “SHR4640 tablet”, 2 entries
  • “SHR4640 dose1”, 2 entries
  • “SHR4640 ;Febuxostat”, 1 entry
  • “SHR4640 ; Febuxostat”, 1 entry

Codes read as this program: SHR4640.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ruzinurad (Jiangsu HengRui Medicine): development program | ClinicalTrials.gg